Adenovirus를 이용한 Uteroglobin 유전자 치료가 실험적 사구체신염에 미치는 영향 = Adenovirus-mediated Gene Therapy of Uteroglobin Protects the Experimental Glomerulonephritis in Mice

다국어 초록 (Multilingual Abstract)

Purpose:Uteroglobin (UG), steroid inducible cytokine-like protein, has potent anti-inflammatory and immunomodulatory action. It is secreted by the mucosal epithelia of virtually all mammals. The aims of this study were to investigate the efficacy of recombinant adenovirus carrying uteroglobin (AdCMV-UG) in prevention and treatment of glomerulonephritis (GN) in mice.
Methods:The AdCMV-UG was created by inserting the uteroglobin cDNA into the pAdTrack- CMV vector and was transfected into the 293 cells through liposome mediated vehicles. AdCMV-UG was injected direct to the both kidneys of 20 mice. In control groups (disease controls), 13 mice received adenoviral vector with GFP and another 11 mice received PBS only. After 5days of viral injection, GN was induced by repetitive intravenous injection of 3.0 mg rabbit anti-GBM Ab to the pretreated mice (C57/B6). Histological and biochemical changes were evaluated 7 and 14 days after injection of anti-GBM Ab.
Results:UG was expressed in the renal tissues and mesangial cells infected with the infection of AdCMV-UG. Pretreatment with AdCMV-UG attenuated the cellular crescent formation 7 days after induction of GN when compared to AdCMV-GFP, PBS only. We also observed reduced mesangial matrix expansion in mice treated with adenovirus carrying UG. Proteinuria was significantly reduced in the mice treated with adenovirus carrying UG when compared with disease control mice (AdCMV-UG 102.2±20.97, AdCMV-GFP 170.6±41.77, and PBS 169.8±55.67, respectively p<0.05 mg/mg). However, at 14 days after anti-GBM Ab injection (total 19 days), there was no significant difference in the amounts of proteinuria and morphologic findings between pretreated and disease control groups.
Conclusion:Adenoviral mediated gene transfer is an effective way of gene delivery. Locally expressed uteroglobin attenuated the severity of glomerulonephritis induced by anti-GBM antibody, although it was transient. Gene therapy using uteroglobin may be constituted for the treatment of human diseases such as chronic GN.

국문 초록 (Abstract)

목 적:저자들은 면역 조절 및 항염증작용을 가진 Uteroglobin (UG)이 면역복합체의 신장 내 침착을 억제하여 사구체신염의 발생을 억제함을 보고한 바 있다. 본 연구에서는 항기저막 사구체신염 (anti-GBM GN) 생쥐모델에서 아데노바이러스를 이용한 UG 유전자의 신장 내 발현이 사구체신염의 발생에 미치는 영향을 평가하고자 하였다.
방 법:아데노바이러스 벡터를 이용한 UG 발현 아데노바이러스 (AdCMV-UG)를 제조하여 8주령의 생쥐 (C57BL/6)의 신장에 주입 후 항기저막 사구체신염 (anti-GBM GN)을 유도하여 신염의 정도를 비교하였다. UG 치료군 (AdCMV-UG)과 질환 대조군 (AdCMV-GFP, PBS only)을 대상으로 anti-GBM GN 유도 후 7일과 14일로 나누어 단백뇨와 신장의 형태학적 변화를 관찰하였다.
결 과:UG 유전자와 단백질은 신장조직과 메산지움 세포에서 발현하였다. 신염 유도 7일째 (총 12일) AdCMV-UG 주입군은 질환 대조군 (AdCMV-GFP, PBS only)에 비해 요단백/ creatinine 값이 유의하게 감소하였으며 (p=0.001), 조직학적으로도 사구체 메산지움 증식과 세포성 반월상 역시 대조군에 비해 감소된 결과를 보였다. 그러나, 신염 유도 14일 (총 19일)로 갈수록 단백뇨나 형태학적으로 UG의 효과는 감소되었다.

참고문헌 (Reference)

• 1 "우리나라 신대체 요법 현황" 18 : 343-354, 1999
• 2 "실험적 사구체신염에 재조합 uteroglobin 투여가 미치는 영향" 21 : 560-568, 2002
• 3 "녹색 형광단백 유전자를 함유한 아데노바이러스 주입시 마우스 생체내 발현양상" 61 : 537-545, 2001
• 4 "“Uteroglobin” a novel cytokine?" 55 : 771-787, 1999
• 5 "crescent formation and Th1 responses in murine glomerulonephritis" 29 : 1-10, 1999
• 6 "Uteroglobin: Physiologic role in normal glomerular function uncovered by targeted disruption of the uteroglobin gene in mice" 32 : 1106-1120, 1998
• 7 "Uteroglobin is essential in preventing immuglobulin A nephropathy in mice" 5 : 1018-1025, 1999
• 8 "Switching off renal inflammation by anti-inflammatory mediators:The facts, the promise and the hopes" 53 : 1118-1126, 1998
• 9 "Successful DNA tranfer in cultured human mesangial cells using replication defective recombinant adenovirus" 46 : 204-209, 1998
• 10 "Strategies of gene transfer to the kidney" 53 : 264-272, 1998
• 11 "Recombinant uteroglobin prevents the experimental creacentic glomerulonephritis" 66 : 1061-1067, 2004
• 12 "Interleukin-4 and interleukin-10 attenuate established crescentic glomerulonephritis in mice" 52 : 52-59, 1997
• 13 "Inhibiting inflammatory cytokines" 16 : 576-582, 1996
• 14 "Immunopathogenesis of renal disease Primer on kidney diseases" Academic press 141-149, 1997
• 15 "Human uteroglobin gene:structure, subchromosomal localization, and polymorphism" 16 : 73-83, 1997
• 16 "Gene transfer technology in therapy:current applications and future goals" 17 : 191-202, 1999
• 17 "Gene transfer into animals The promise of adenovirus" In Cohen-Haguenauer Q -61, 1991
• 18 "Gene therapy for renal diseases" 52 (52): 85-88, 1997
• 19 "Dysregulation of cytokine expression in tubulointerstitial nephritis associated with murine malaria" 53 : 845-852, 1998
• 20 "Development of adenovirus vectors for the expression of heterologous genes" 616-6 629, 1988
• 21 "Chemokines:A new classification system and their role in immunity" 12 : 121-127, 2000
• 22 "Adenoviral-mediated uteroglobin gene transfer inhibits neointimal hyperplasia after balloon injury in the rat carotid artery" 32 : 111-117, 2000
• 23 "Adenoviral mediated uteroglobin gene transfer to the adventitia reduces arterial intimal hyperplasia" 99 : 377-380, 2001
• 24 "A simple technique for the rescue of early region 1 mutations into infectious human adenovirus type 5" 614-163 617, 1988
• 25 "A role for uteroglobin in glomerulopathy knockout mice as a model system" 30 : 720-724, 1997
• 26 "A new technique for the assay of infectivity of adenovirus 5 DNA" 456-52 467, 1973